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Possible harms of oseltamivir—a call for urgent action 
 
Oseltamivir is a successful drug: between July, 2004, to June, 2009, more than 11·5 
million new prescriptions were issued in the USA, and nearly all influenza pandemic 
plans recommend antiviral drugs as a mainstay of containment on a population basis 
and treatment on an individual basis, with oseltamivir preferred because of ease of 
administration and storage. As 75% of the world production of oseltamivir has been 
used in Japan,1
 
 this is where to look for any serious harms the drug might cause. 
In March, 2007, the Japanese Ministry of Health Labour and Welfare funded two 
prospective cohort studies, and subsequently advised against oseltamivir's use in 
children and adolescents aged 10–19 years. The first study was in 2846 children in 
the winter of 2005–06. This study found evidence of unusual behaviour in recipient 
children within the first day of infection.1 The second larger (>10 000 children) cohort 
study done the following winter failed to find any positive association. However, the 
analysis was criticised.1 A detailed independent review of eight serious cases 
concluded that three sudden deaths during sleep and two near-deaths, as well as 
two deaths from accidents resulting from abnormal behaviour in older children and 
adolescents shortly after taking oseltamivir, were probably related to the central 
depressant action of oseltamivir.
 
2 
As part of updating our 2006 Cochrane review on neuraminidase inhibitors,3 we are 
assessing possible harms, and first examined the randomised controlled trials 
(RCTs). These trials most commonly reported vomiting in adolescents (risk 
difference 0·05, 95% CI 0·02–0·09, number needed to harm 20)4 and nausea in 
healthy adults (odds ratio 1·79, 95% CI 1·10–2·93), but no behavioural disturbances 
or deaths.3 We looked for harm data outside RCT evidence, submitting a Freedom of 
Information Act request to the US Food and Drug Administration (FDA) for all harms 
data in their possession. We received Adverse Event Reporting System (AERS) data 
from 1999, supplementing the freely accessible FDA AERS data since 2004.
 
5,6 
The FDA dataset includes 2275 initial postmarketing surveillance adverse event 
reports generated worldwide from December, 1999, to July, 2009 (the date of 
granting our request). Breakdown by setting and even country is difficult because 
most reports do not indicate these variables and the only date consistently recorded 
is the date the FDA received the report (which could be several months or even 
years after the event). The data do not allow standardisation by doses sold or by 
level of circulating influenza, which prevents estimates of reporting rates or seasonal 
trends. Despite these limitations, many (607/1781, 34%) serious harms were 
reported in people aged below 20 years. Abnormal behaviour, convulsion, delirium, 
and hallucinations were more common in the young, while other adverse effects 
(diarrhoea, headache, nausea, loss of consciousness, pyrexia, and vomiting) were 
not. The most common globally reported potential harms (those which generated at 
least 50 reports) for oseltamivir are shown in the table. 
 
Since July, 2005, the reporting country was identified in 99·6% of reports. The US 
reporting rate of adverse events was 0·43 per 10 000 total oseltamivir prescription 
counts from July, 2005, to March, 2009. However, the FDA AERS data were not of 
sufficient quality to answer our study question. For example, adverse events listed 
for each report were given in alphabetical order, not in order of importance. 
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Information about the patient’s setting, symptoms, and timing of the event were often 
insufficiently precise, missing, or absent, which made interpretation of reports 
impossible. Reports of delirium and confusion could be caused by oseltamivir in 
children and adolescents. But they could equally be a manifestation of a high 
temperature due to influenza or influenza-like illness.7 Finally, national pandemic 
stockpiling as well as personal stockpiling indicates that neither sales nor even 
prescription data may equate with exposure to the drug.
 
8 
Despite these inadequate data, the consistent reports of potential serious harms in 
adolescents, and the projected future heavy use of oseltamivir, make it imperative to 
quickly establish large multicentre studies to test any possible associations. The 
choice of design might prove controversial. Ethical concerns or a supposed rare 
incidence suggest a case-control design. But if the best estimates from Japan are 
reliable (a 3% incidence in children using oseltamivir for behavioural changes within 
a few days—estimates that beg the question of why registration trials did not pick 
them up), RCTs would be the best. Whichever way, we are running out of time to 
find answers. 
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Table: Most frequently reported potential harms after ingestion of oseltamivir 
(up to 20 per patient) by age-group according the US FDA AERS postmarketing 
surveillance database, 1999 – 2009. 
From initial reports only. AERS database describes events with the Preferred Term 
(PT) level medical terminology, with use of the Medical Dictionary for Regulatory 
Activities (MedDRA). 
 
Description of 
event 
Age<20 years 
(n=607) 
Age >20 
years 
(n=1174) 
Missing age 
(n=494) 
Total 
(n=2275) 
Abnormal 
behaviour 
145 34 34 213 
Confusional 
state 
15 28 14 57 
Convulsion 49 37 12 98 
Delirium 54 23 15 92 
Diarrhoea 20 42 21 83 
Hallucination 89 35 21 145 
Headache 9 30 12 51 
Loss of 
consciousness 
18 34 0 52 
Nausea 13 63 30 106 
Pyrexia 18 36 12 66 
Vomiting 49 92 50 191 
 
